FOSTER CITY, Calif.--(BUSINESS WIRE)--Aug. 3, 2009--
Gilead Sciences, Inc. (Nasdaq:GILD) today announced the promotion of
Gregg H. Alton to Executive Vice President, Corporate and Medical
Affairs. He was previously Senior Vice President and General Counsel,
responsible for legal, government and public affairs and international
access operations, and recently assumed the additional responsibility of
management for Gilead’s global medical affairs activities and personnel.
Mr. Alton will continue to report to John C. Martin, PhD, Gilead’s
Chairman and Chief Executive Officer.
“Gregg has established and built a number of critical functions at
Gilead, and in doing so has demonstrated his leadership and his
understanding of how every part of our organization contributes to
delivering therapies to patients,” said Dr. Martin. “Gregg’s knowledge
of public health and health policy will be instrumental to our medical
affairs efforts across therapeutic categories. His promotion is
recognition of Gregg’s many contributions to our company and the
importance of his continued leadership and vision.”
Mr. Alton joined Gilead Sciences in 1999. From 2000 to 2009 he served as
General Counsel. Prior to joining Gilead, Mr. Alton was an attorney at
the law firm of Cooley Godward, LLP, where he specialized in mergers and
acquisitions, corporate partnerships and corporate finance transactions
for healthcare and information technology companies. Mr. Alton received
a bachelor’s degree in legal studies from the University of California
at Berkeley, and holds a JD from Stanford University.
About Gilead Sciences
Gilead Sciences is a biopharmaceutical company that discovers, develops
and commercializes innovative therapeutics in areas of unmet medical
need. The company’s mission is to advance the care of patients suffering
from life-threatening diseases worldwide. Headquartered in Foster City,
California, Gilead has operations in North America, Europe and Australia.
For more information on Gilead, please call the Gilead Public Affairs
Department at 1-800-GILEAD-5 (1-800-445-3235) or visit www.gilead.com.
Source: Gilead Sciences, Inc.
Gilead Sciences, Inc.Patrick O’Brien, 650-522-1936 (Investors)Amy
Flood, 650-522-5643 (Media)
